Current Status and Growth of Nuclear Theranostics in Singapore

Abstract

The concept of theranostics, where individual patient-level biological information is used to choose the optimal therapy for that individual, has become more popular in the modern era of 'personalised' medicine. With the growth of theranostics, nuclear medicine as a specialty is uniquely poised to grow along with the ever-increasing number of concepts combining imaging and therapy. This special report summarises the status and growth of Theranostic Nuclear Medicine in Singapore. We will cover our experience with the use of radioiodine, radioiodinated metaiodobenzylguanidine, peptide receptor radionuclide therapy, prostate specific membrane antigen radioligand therapy, radium-223 and yttrium-90 selective internal radiation therapy. We also include a section on our radiopharmacy laboratory, crucial to our implementation of theranostic principles. Radionuclide theranostics has seen tremendous growth and we hope to be able to grow alongside to continue to serve the patients in Singapore and in the region.

Nuclear Theranostics in Asia: In vivo Companion Diagnostics

“…In this issue [12][13][14][15][16] and online [37][38][39][40][41][42] and also the following issues, we will see the current status of state-of-art theranostics in Asian countries, however, beyond the geographic extension of nuclear theranostics, disciplinary expansion above the current obsession with peptides or small molecules, or above a few successful tumors are to be expected with full inspiration in our collective mind of nuclear medicine community. Asian colleagues and also all the colleagues, either current or next-generation leaders, regardless of their nationality with various economic status of their own countries, will develop the novel in vivo theranostics including nuclear theranostics.…”